304 related articles for article (PubMed ID: 32370462)
1. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Jia YJ; Liu H; Wang LR; Wang T; Feng R; Chen YJ; Wang M; Guo HX; Wen L; Duan WB; Yang YZ; Wang FR; Chen YY; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):347-352. PubMed ID: 32370462
[No Abstract] [Full Text] [Related]
2. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
3. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Liu J; He HY; Li L; Lu J; Qiang WT; Guo P; Hou N; Jiang H; Du J; Fu WJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):27-32. PubMed ID: 33677865
[No Abstract] [Full Text] [Related]
4. [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma].
Zhao AL; Tang WJ; Li Y; Liao Y; Li H; Wang J; Shen K; Yang YF; Xu J; Zhang L; Zheng YH; Niu T
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(41):3304-3311. PubMed ID: 36319183
[No Abstract] [Full Text] [Related]
5. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K
Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience.
Byun JM; Yoon SS; Koh Y; Kim I; Jo J; Park H; Lee JO; Lee J
Anticancer Res; 2019 Sep; 39(9):5165-5170. PubMed ID: 31519629
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
[TBL] [Abstract][Full Text] [Related]
9. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
10. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
11. Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.
Park SS; Eom HS; Kim JS; Koh Y; Choi CW; Lee JJ; Kim K; Suh C; Lee JH; Min CK;
Jpn J Clin Oncol; 2019 Jan; 49(1):92-95. PubMed ID: 30476124
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis.
Cao C; Zhou X; Ma Q
Pharmacol Res Perspect; 2021 Aug; 9(4):e00797. PubMed ID: 34128350
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Usmani SZ; Nahi H; Mateos MV; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Luo M; Liu K; San-Miguel J
Blood; 2019 Aug; 134(8):668-677. PubMed ID: 31270103
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study.
Iida S; Suzuki K; Kusumoto S; Ri M; Tsukada N; Abe Y; Aoki M; Inagaki M
Int J Hematol; 2017 Oct; 106(4):541-551. PubMed ID: 28643017
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study.
Kumar L; Melinkeri S; Ganesan P; Kumar J; Biswas G; Kilara N; Pathalingappa H; Prasad S; Jain M; Mishra SK; Prasad S; Boyella PK; Sahoo RK; Bondarde S; Shah S; Rege M; Deb U; Korde T; Dixit J
Future Oncol; 2024 Feb; 20(4):191-205. PubMed ID: 38116642
[TBL] [Abstract][Full Text] [Related]
18. Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.
Minarik J; Pour L; Maisnar V; Spicka I; Jungova A; Jelinek T; Brozova L; Krhovska P; Scudla V; Hajek R
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Sep; 163(3):279-283. PubMed ID: 30397362
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).
Jing H; Yang L; Qi J; Qiu L; Fu C; Li J; Yang M; Qi M; Fan N; Ji J; Lu J; Li Y; Jin J
Ann Hematol; 2022 Dec; 101(12):2679-2690. PubMed ID: 36301338
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of efficacy and safety of daratumumab-containing regimen in relapsed and refractory multiple myeloma patients].
Yu QR; Zhou X; Wu HY; Hao LM; Li XM; Zhong YP
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):521-525. PubMed ID: 38317364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
